---
title: "Regeneron beats quarterly estimates on eczema drug strength, shares rise"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294359627.md"
datetime: "2026-07-30T11:52:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294359627.md)
  - [en](https://longbridge.com/en/news/294359627.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294359627.md)
generator: "portal-rs"
---

# Regeneron beats quarterly estimates on eczema drug strength, shares rise

July 30 (Reuters) - Regeneron (REGN.O) on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea.

Shares rose nearly 5% before the bell.

Here are the details:

-   Global net sales of Dupixent, recorded by partner Sanofi (SASY.PA) , increased 38% to about $6 billion, beating estimates of $5.34 billion, according to LSEG data.
-   Quarterly U.S. sales of the high dose version of its eye drug, Eylea, rose 52% to $596 million, driven by higher demand and sales volumes, partly offset by lower prices.
-   The company said sales of the lower-dose version were hurt by continued competitive pressures and the transition of patients to the 8-mg version.
-   Regeneron said it fully repaid the Sanofi Development Balance, which represented the outstanding amount due to Sanofi for its funding of prior collaboration development activities.
-   Marked commercial outperformance may help boost sentiment, and, coupled with the step-up in margins from the Sanofi repayment, should make second half numbers look much better, said RBC Capital Markets analyst Brian Abrahams.
-   Quarterly revenue rose 17% to $4.29 billion, surpassing estimates of $3.82 billion.
-   The Tarrytown, New York-based drugmaker posted a quarterly non-GAAP adjusted profit of $14.29 per share, beating the analyst estimate of $10.26.

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

- [B. Metzler seel. Sohn & Co. AG Grows Stock Position in Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/298098855.md)
- [10:07 ETREGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact SueWallSt](https://longbridge.com/en/news/297926980.md)
- [Pharvaris rises on late-stage trial win for hereditary angioedema drug](https://longbridge.com/en/news/298315480.md)
- [Archford Capital Strategies LLC Invests $1.42 Million in Sanofi $SNY](https://longbridge.com/en/news/298552558.md)
- [Intelligent Bio Submits Comprehensive Clinical Data to Enter US Drug Screening Market](https://longbridge.com/en/news/298460374.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**